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Introduction {#sec001}
============

Since the first report of a case of Middle East respiratory syndrome coronavirus (MERS-CoV) in Saudi Arabia in 2012, 2,519 laboratory-confirmed patients and 866 deaths (34.3% mortality) have been reported as of January 2020 \[[@pone.0232757.ref001]\]. Laboratory confirmed cases have been reported in 27 countries globally, most of which were caused by human-to-human transmission in household or healthcare settings besides cases of primary infection \[[@pone.0232757.ref002]\]. The largest outbreak outside of the Arabian Peninsula occurred in South Korea in 2015, with a total 186 confirmed cases and 38 deaths (20.4% mortality) \[[@pone.0232757.ref003]\].

No vaccine or therapeutic agent has been approved for the prevention and treatment against MERS-CoV infection to date. Several laboratory studies proposed vaccine candidates, based on the receptor-binding domain (RBD) of spike (S) antigen, which induce neutralizing antibodies. These antibodies inhibit RBD from binding the host receptor dipeptidyl peptidase 4 (hDPP4; also known as CD26) \[[@pone.0232757.ref004]\], An alternative strategy is to use virus-specific therapeutic human antibodies that can be rapidly developed to neutralize the virus during infection. Indeed, some monoclonal antibodies (mAbs) cloned from humans using various platforms have shown considerable MERS-CoV-neutralizing potency along with therapeutic or prophylactic efficacies in animal models \[[@pone.0232757.ref005]--[@pone.0232757.ref012]\]. Additionally, nanobodies and camel/human hybrid antibodies have been suggested for treatment of viral infection \[[@pone.0232757.ref013], [@pone.0232757.ref014]\]. Most recently, a research group isolated mAbs from a MERS patient via B cell immortalization, which showed promising therapeutic and prophylactic potential against MERS-CoV infection in a mouse model \[[@pone.0232757.ref008]\]. Moreover, targeting multiple antigenic sites on spike might be advantageous, suggesting the possibility of combination therapy with RBD-specific antibodies for escape-mutant prevention \[[@pone.0232757.ref011], [@pone.0232757.ref015]\]. To date, two phase I human clinical trials of therapeutic antibody candidates, humanized mAbs (REGN3048, REGN3051) and human polyclonal anti-MERS immunoglobulin G (IgG; SAB-301) from transchromosomic cattle have been completed \[[@pone.0232757.ref016], [@pone.0232757.ref017]\]. The clinical trial result of SAB-301 shows that SAB-301 appears to be safe and well-tolerated in healthy individuals, encouraging expectations for the development of MERS therapeutics \[[@pone.0232757.ref016]\].

Despite two decades of extensive research and development of therapeutic antibodies against viral infections (numerous clinical trials have been performed for both acute and chronic infections), only palivizumab and ibalizumab have been approved for monoclonal prophylaxis of human respiratory syncytial virus and human immunodeficiency virus infections, respectively \[[@pone.0232757.ref018], [@pone.0232757.ref019]\]. Several strategies are available for the development of therapeutic human mAbs for viral infections; in the present study, we isolated single B cells from patients for development. A MERS-CoV S antigen trimer probe (S-2P) was designed to retain betacoronavirus S proteins in the prefusion conformation \[[@pone.0232757.ref020]\]. It increased antigenicity and affinity binding to hDPP4. It also elicited high titers of neutralizing antibodies in mice. Previous reports, including MERS-CoV, SARS-CoV, HIV and RSV, showed that structure-designed stabilization of the viral surface protein by mutations induced greater neutralizing mAbs than postfusion proteins \[[@pone.0232757.ref020]--[@pone.0232757.ref023]\].Thus, we rationally designed a strategy to develop the potent neutralizing antibodies against MERS-CoV infection by using an S-2P. We directly isolated B cells from the peripheral blood mononuclear cells (PBMCs) of convalescent patients using an S-2P for cell sorting, cloned the IgG genes, and produced antibodies through cell culture \[[@pone.0232757.ref015]\]. We also evaluated the binding affinity for S protein and the RBD of the obtained mAbs and determined the neutralizing ability with a pseudovirus and plaque- reduction neutralizing assay (PRNT) *in vitro*. Finally, we examined the therapeutic efficacy of the mAb with the strongest neutralizing activity in transgenic (TG) mice challenged with a lethal dose of MERS-CoV. These results offer a new platform and antibody for prompt development toward clinical trials.

Materials and methods {#sec002}
=====================

Clinical specimens and ethics statement {#sec003}
---------------------------------------

PBMCs and serum were collected from three convalesced MERS-CoV Korean patients 1 month after diagnosis and deposited at the National Human Resource Bank (NHRB). Cryopreserved specimens were obtained from the NHRB after the research protocols were approved by the Korea Centers for Disease Control and Prevention Institutional Review Board (IRB No. 2016-05-01). All specimens were fully anonymized.

Single B cell isolation by flow cytometry {#sec004}
-----------------------------------------

MERS-CoV S-reactive single B cells were sorted into 96-well plates as previously described \[[@pone.0232757.ref015]\]. Briefly, cryopreserved PBMCs were thawed in a 37°C water bath, added to 20 ml of wash buffer \[phosphate-buffered saline (PBS) containing 10% fetal bovine serum and 2 U/ml DNase I\] and centrifuged at 200 g for 8 min. The cells were resuspended with 10 ml of PBS and placed on a 40-μm nylon cell strainer (BD Bioscience, San Jose, CA, USA) to remove aggregated cells. After centrifugation, cells were stained with a LIVE/DEAD Fixable Violet Dead Cell Stain Kit (Life Technologies, Carlsbad, CA, USA) and incubated with 200 μl of an anti-human antibody cocktail, including CD3 (BV421; BD Bioscience), CD4 (BV421; BioLegend, San Diego, CA, USA), CD8 (BV421; BioLegend), CD14 (BV421; BioLegend), CD20 (PerCP Cy5; BioLegend), and IgG (FITC; BD Bioscience) antibodies, along with PE-labeled S-2P trimer \[[@pone.0232757.ref020]\] and APC-labeled S1 for 20 min in the dark. Except for B cell, other immune cells were excluded by negative selection, then S-2P trimer- and/or S1 probe-positive single B cells were sorted by flow cytometry on a FACSAria III cell sorter (BD Bioscience) and then directly collected into a 96-well polymerase chain reaction (PCR) plate containing RNase OUT (Invitrogen, Carlsbad, CA, USA), 5× First-Strand Buffer (Invitrogen), 0.1 M dithiothreitol (Invitrogen), and Igepal (Sigma-Aldrich, St Louis, MO, USA).

Reverse transcription (RT) and nested PCR for human IgG genes {#sec005}
-------------------------------------------------------------

RT was performed directly by adding a random hexamer primer (Invitrogen), 10 mM dNTP (Invitrogen), and reverse transcriptase Superscript III (Invitrogen) in 96-well PCR plate and incubated as follows: 42°C for 10 min, 25°C for 10 min, 50°C for 50 min, and 94°C for 5 min. The variable regions of Ig heavy and light-chain genes were amplified using primers as reported previously \[[@pone.0232757.ref024]\]. For the first-round of PCR, 5 μl of cDNA templates were added to the reaction mixture containing 5 μl 10× PCR buffer, 1 μl 25 mM MgCl~2~, 0.5 μl 10 mM dNTP (Fermentas, Waltham, MA, USA), 1 μl of forward and reverse primers (25 μM each), 0.3 μl HS Taq Plus Polymerase (Qiagen, Hilden, Germany), and 36.2 μl nuclease-free water. The PCR cycle was initiated by 5-min incubation at 94°C, followed by 15 cycles of 94°C for 30 s, 51°C for 30 s, 72°C for 1 min, and 30 cycles of 94°C for 30 s, 56°C for 30 s, and 72°C for 1 min. Subsequent nested PCR was performed with a reaction mixture containing 3 μl of the first PCR amplicon, 5 μl 10× PCR buffer, 10 μl solution Q (Qiagen, Hilden, Germany), 0.5 μl 10 mM dNTP, 1.5 μl forward and reverse primers (25 μM each), 0.3 μl HS Taq Plus Polymerase, and 28.2 μl nuclease-free water. The second PCR cycle was initiated by 4-min incubation at 94°C, followed by 50 cycles of 94°C for 30 s, 57°C for 30 s, 72°C 30 s, and final extension at 57°C for 30 s. PCR products were visualized on 2% agarose gels, and positive samples were analyzed by sequencing with 3′-end primers.

Cloning and expression of IgG {#sec006}
-----------------------------

Paired heavy and light-chain genes were cloned into an expression vector, and IgGs were expressed from transfected Expi293 cells as described previously \[[@pone.0232757.ref015]\]. Briefly, each heavy and light-chain sequence was evaluated using the IMGT-QUEST tool which provides single chain fragment variable and each sequence productivity \[[@pone.0232757.ref025]\]. Then, the variable regions of heavy (VH) and light (VK or VL) chains were cloned into expression vectors (VRC2271, VRC2272 and VRC2276) containing constant regions of human immunoglobulin heavy (γ), light κ, and λ chains, respectively. Same amounts of heavy and light-chain vectors were co-transfected into Expi293 cells using the ExpiFectamine 293 transfection kit (Thermo Fisher Scientific, Carlsbad, CA, USA) according to manufacturer instructions. Cells were incubated for 4 to 5 days at 37°C and 8% CO~2~; subsequently, cells were centrifuged at 2500 g, and supernatants were harvested. IgG was purified using protein A Sepharose 4 Fast Flow (GE Healthcare, Uppsala, Sweden).

Enzyme-linked immunosorbent assay (ELISA) {#sec007}
-----------------------------------------

The 96-well Maxisorp plates (Nunc, Roskilde, Denmark) were coated with a previously reported recombinant MERS-CoV S-2P trimer \[[@pone.0232757.ref020]\], RBD, S1, or S2-mFc (S2-fusion with murine Fc for solubility and stability) protein \[[@pone.0232757.ref015]\] (0.1 μg/well) in PBS at 4°C overnight. Subsequently, plates were blocked with blocking buffer (5% skim milk and 2% bovine serum albumin in PBS) at room temperature for 1 h and washed three times with PBS containing 0.05% Tween-20. Then, serial 4-fold-diluted mAbs were added to each well, incubated for 1 h, and washed three times with PBS containing 0.05% Tween-20. Horseradish peroxidase-conjugated anti-human IgG (Jackson Laboratory, Bar Harbor, ME, USA) was used as a secondary antibody. The color signal was developed by tetramethylbenzidine (KPL, Gaithersburg, MD, USA), and the reaction was stopped by adding 1 N H~2~SO~4~ (Thermo Fisher Scientific). Absorbance at an optical density of 450 nm was measured using a microplate reader (Molecular Devices, Sunnyvale, CA, USA).

Pseudovirus-neutralization assay and PRNT {#sec008}
-----------------------------------------

Pseudovirus-neutralization assay (for EMC) with luciferase activity \[[@pone.0232757.ref015]\] and PRNT assay (for EMC and MERS-CoV/KOR/KNIH/002_05_2015 (KNIH-002) strains) were performed as described previously \[[@pone.0232757.ref026]\]. Briefly, serial 4-fold-diluted mAbs and an equal volume of virus (40 pfu/well) were incubated at 37°C for 2 h. The mixture was added to each well of a 24-well plate seeded with Vero cells (1 × 10^5^ cells/well) and incubated at 37°C for 1 h, followed by addition of 1 ml of 1.5% carboxymethylcellulose on the medium. After 3 to 4 days of incubation, the cells were fixed with 4% paraformaldehyde and stained with crystal violet to visualize the plaques. All assays were performed in triplicate for each mAbs. The half-maximal inhibitory concentration (IC~50~) of each mAb was calculated from dose-response plots using GraphPad Prism software (GraphPad, La Jolla, CA, USA).

Binding affinity of the mAbs to S1 and RBD {#sec009}
------------------------------------------

The binding affinities of the mAbs to MERS-CoV S antigen were determined by a surface plasmon resonance (SPR) assay with a Biacore T200 instrument (GE Healthcare) \[[@pone.0232757.ref027]\]. Briefly, purified MERS-CoV S1 or RBD protein was immobilized onto a CM5 chip in 1× PBS buffer (pH 7.4). Different concentrations of RBD-specific mAbs (KNIH77-A5, KNIH77-A6, KNIH90-B2, KNIH90-B7, KNIH90-F1, and KNIH90-F2) were run in HBS-EP buffer. The surface was regenerated with 10 mM NaOH or 10 mM glycine-HCl (pH 2.0). Sensograms were fit with a 1:1 binding model using BIA Evaluation software (GE Healthcare).

Computational structure modeling {#sec010}
--------------------------------

The RBD (positions 367--606 in the full S protein) of the S protein was modeled using the I-TASSER web service (zhanglab.ccmb.med.umich.edu/I-TASSER) \[[@pone.0232757.ref028]\]. The variable region structure of the human neutralizing antibody KNIH90-F1 was generated by Rosetta Antibody modeling in ROSIE (<http://rosie.graylab.jhu.edu/antibody>) \[[@pone.0232757.ref029]\]. Docking simulation with the RBD/KNIH90-F1 complex was performed using the SnugDock program in ROSIE \[[@pone.0232757.ref030]\]. Modeled structures of the RBD and KNIH90-F1 were used as the starting structures for the docking study. Structural alignment and visualization were performed with the PyMOL program (The PyMOL Molecular Graphics System, v.2.0; Schrodinger, LLC, New York, NY, USA).

Mice and ethics statement {#sec011}
-------------------------

All animal experiments were performed in strict accordance with the Guidelines for the Care and Use of Laboratory Animals of Korea National Institute of Health (KNIH). The protocol was approved by the Institutional Animal Care and Use Committee of the KNIH (Protocol approval No. KCDC-090-18-2A). C57BL/6N mice were purchased from Orient Bio (Iksan, Republic of Korea). Cages were changed once per week until the end of the experiment, and food and water replenished as often as was necessary.

Assessment of therapeutic and prophylactic effects of mAb in mice {#sec012}
-----------------------------------------------------------------

The wild-type MERS-CoV animal challenge experiment was performed under animal biosafety level 3 containment and practice. Ten-week-old male C57BL/6N mice expressing hDPP4 (C57BL/6N-hDPP4) conjugated with a FLAG tag were generated according to the method previously described for developing a TG mouse expressing hDPP4 \[[@pone.0232757.ref031]\]. Prior to lethal challenge, 50% mean lethal dose (LD~50~) in mice was determined according to the previously described method \[[@pone.0232757.ref032]\]. LD~50~ of MERS-CoV KNIH-002 is 1 × 10^3^ pfu per mouse. Five mice were inoculated with a 100-fold LD~50~ (1 × 10^5^ pfu) of MERS-CoV KNIH-002 strain via intranasal route, whereas three different doses (8 mg/kg, 2 mg/kg, and 0.4 mg/kg; n = 9 per dose) of the mAb (KNIH90-F1) or PBS were administered intraperitoneally on day 1 post-infection. Four mice in the group treated at the highest dose (8 mg/kg) were humanely euthanized by intraperitoneal injection using a mix of 30 mg/kg Zoletil® (Virbac, Carros, France) and 10 mg/kg Rompun® (Bayer, Leverkusen, Germany) on day 4 post-infection, and lungs and brains were harvested for analysis of MERS-CoV replication. After brain and lung tissue weights were measured, tissue samples in 1 mL of DMEM media were homogenized, and MERS-CoV was titrated by plaque assay and real-time RT-PCR. To measure the virus titer, tissues were homogenized in DMEM using a manual homogenizer and centrifuged for 10 min. Viral RNAs were extracted from the supernatant by Maxwell RSC Viral TNA kit (Promega) and were assayed by using PowerChek^TM^ MERS (upE & ORF1a) Real-time RT-PCR kit (Kogene biotech) according to the manufacturer\'s instructions. To generate the standard RNA of upE, upE RT-PCR was performed with SuperScript III reverse transcriptase (Invitrogen, Carlsbad, CA, USA) using MERS-CoV EMC as an RNA template. For PCR, 5 μl of the RT reaction was added to 20 μl of PCR amplification master mix containing Ex-Taq^™^ polymerase (Takara, Shuzo, Japan). After PCR purification with a PCR purification kit (Qiagen), 1 μl of pCR®2.1-TOPO® vector (Invitrogen) was added to the purified PCR products, and the mixture was transformed into One Shot® Top10 competent cells (Invitrogen). The standard RNAs were synthesized massively using a MEGAscript® T7 kit (Applied Biosystems) and the template plasmids pCR2.1-upE. The RNAs were purified by MEGAclear^™^ kit (Applied Biosystems). RNA copy numbers were calculated based on RNA concentration and size. The upE RNA fragment was diluted serially with a 0.5 log-dilution to yield 1 to 105 copies per reaction, and these dilutions were then used as templates for rRT-PCR. Then, the Ct values of tissues and copy numbers were calculated.

Vero cell monolayers were inoculated with serial 10-fold dilutions of the supernatant, which was adsorbed for 1 hr. The cells were covered with 1 ml or 1.5% CMC solution. After 3 days, the cells were washed with PBS and fixed with 4% formaldehyde and stained with crystal violet. The body weight of the remaining five mice in each group was monitored daily for 14 days, and mice showing a weight loss of more than 25% of their initial body weight were euthanized by CO~2~ gas and recorded as dead. The remaining five mice in each group were observed for 14 days for survival analysis. To evaluate the prophylactic effect, an additional four mice were pretreated with 8 mg/kg of the mAb 1 day before the challenge, and viral replication in lung and brain tissues was determined on day 4 post-infection.

Histology {#sec013}
---------

Six mice in each group were performed according to the same experiment design for the therapeutic efficacy in the previous section. Three mice in each group were humanely euthanized on days 4 and 7 post-infection, and lung and brain tissues were harvested for histopathological evaluation. The tissues were fixed in formalin, embedded in paraffin blocks, sectioned, followed by hematoxylin and eosin (H&E) staining.

Real-time RT-PCR for virus detection {#sec014}
------------------------------------

MERS-CoV viral RNAs were detected by one-step real-time RT-PCR as previously described \[[@pone.0232757.ref033]\]. Briefly, viral RNAs were extracted from homogenized mouse tissues using the Maxwell RBC RNA TNC kit (Promega, Fitchburg, WI, USA). Real-time RT-PCR was conducted with the PowerChek MERS assay (Kogenebiotech, Seoul, Republic of Korea) to detect *Orf1a* genes according to manufacturer instructions. Five microliters of template RNA was added to the reaction mixture, and the following PCR cycling program was used: 50°C for 30 min, followed by 95°C for 10 min and 40 cycles of at 95°C for 15 s and 60°C for 60 s.

Statistical analysis {#sec015}
--------------------

Group comparisons were performed by a paired Student's *t* test in Prism 7 (GraphPad Software, San Diego, CA, USA). Differences were considered significant at *P* \< 0.05.

Results {#sec016}
=======

Generation and binding specificity of MERS-CoV mAbs {#sec017}
---------------------------------------------------

We separated MERS-CoV S-binding single B cells from the PBMCs of three convalescent Korean MERS patients using flow cytometry cell sorting. IgG heavy and light (kappa or lambda) chain variable regions were amplified by nested PCR from 90 sorted B cells (24 cells from a patient and 66 cells from pooled two patient's PBMCs), cloned into expression vectors, and expressed in Expi293 cells after transient transfection, followed by purification of 11 IgGs from culture supernatants using protein A beads. The total protein yields ranged from 1 mg/mAb to 25 mg/mAb per 200-ml culture. Evaluation of the binding specificities of the purified IgGs by ELISA coated with soluble S-2P trimer, S1, RBD, and S2-mFc antigens revealed that six antibodies (KNIH77-A5, KNIH77-A6, KNIH90-E5, KNIH90-E6, KNIH90-F1, and KNIH90-F2) bound to S-2P trimer, S1, and RBD and were thus considered to be RBD-specific ([Fig 1](#pone.0232757.g001){ref-type="fig"}). The other five antibodies (KNIH90-A3, KNIH90-A9, KNIH90-B2, KNIH90-B7, and KNIH90-C4) bound to the S-2P trimer and S1 but not RBD; however, we identified no S2 domain-specific antibody, as this domain has relatively low immunogenicity as compared with the variable S1 domain. Only KNIH90-C4 bound to prefusion S trimer more strongly than S1 protein in ELISA ([Fig 1B](#pone.0232757.g001){ref-type="fig"}). Also, the specificity of mAbs were tested in immunofluorescence assay (IFA) with other coronaviruses, human coronavirus (HCoV)-OC43, HCoV-229E, HCoV-NL63, and SARS-CoV-2. All mAbs were specific for MERS-CoV. All mAbs showed no indication of binding to other coronavirus strains tested ([S3 Fig](#pone.0232757.s003){ref-type="supplementary-material"}).

![Binding of human mAbs to S1 and RBD of the MERS-CoV S protein.\
Binding specificity of the mAbs was assessed by ELISA with a soluble S-2P trimer, S1, RBD sub-domains, and S2-mFc. Among the 11 purified mAbs, six were specific to RBD and five were specific to S1 (non-RBD). RBD-specific mAbs bound to both RBD and S1 protein. No S2-specific mAbs (blue line) were identified. Data points represent the mean of three technical replicates with standard errors.](pone.0232757.g001){#pone.0232757.g001}

Neutralization activity of the mAbs {#sec018}
-----------------------------------

We initially evaluated the neutralization potency of the mAbs using MERS-CoV (EMC) pseudovirus. Among the 11 purified mAbs, the five S1 (non-RBD)-specific mAbs failed to inhibit pseudovirus particles, but five of the six RBD-specific mAbs showed high neutralization capacity, with KNIH90-E6 failing to reach 50% inhibition, even at the highest mAb concentration tested ([Fig 2A](#pone.0232757.g002){ref-type="fig"}). The IC~50~ values for the RBD-specific mAbs varied between 0.2173 μg/ml and 0.0089 μg/ml, with KNIH90-F1 demonstrating the most potent inhibition ([Table 1](#pone.0232757.t001){ref-type="table"}, [S1 Fig](#pone.0232757.s001){ref-type="supplementary-material"}). Similar results were obtained in the PRNT assay using wild-type MERS-CoV (EMC) virus ([Fig 2B](#pone.0232757.g002){ref-type="fig"}). Therefore, we identified KNIH90-F1 as the most potent RBD-specific mAb against MERS-CoV (EMC and KNIH-002) in both the pseudovirus neutralization assay (IC~50~: 0.0135 μg/ml) and PRNT assay (IC~50~: 0.006 μg/ml) ([Table 1](#pone.0232757.t001){ref-type="table"}, [S1 Fig](#pone.0232757.s001){ref-type="supplementary-material"}). However, in contrast to the pseudovirus neutralization assay, some S1-specific (non-RBD) mAbs (KNIH90-B2 and KNIH90-B7) also moderately inhibited the wild-type virus, although to a lesser extent than the RBD-specific mAbs ([Fig 2B](#pone.0232757.g002){ref-type="fig"}). Spike of the KNIH-002 strain has four amino acid changes (S137R, I529T, V530L, and R629H), compared to EMC strain \[[@pone.0232757.ref034]\]. Among them, I529T and V530L mutations were located in the RBD, but not at the RBD-DPP4 receptor interface \[[@pone.0232757.ref035]\]. Thus, we assumed that KNIH90-F1 would have similar neutralizing activities and affinities between MERS-CoV KNIH-002 strain and EMC strain. As we expected, this antibody showed potent neutralizing activity against both MERS-EMC and KNIH-002 strains.

![Neutralizing activity of mAbs specific for S1 and the RBD of the S protein.\
Neutralization potency of RBD and S1-specific mAbs evaluated using a MERS-CoV EMC pseudovirus-neutralization assay (A) and a live-virus PRNT assay (B). The percent inhibition by the mAbs was determined by comparison with untreated cells. Each experiment was performed in triplicate, and data represent the mean of each experiment with standard errors.](pone.0232757.g002){#pone.0232757.g002}

10.1371/journal.pone.0232757.t001

###### Neutralization activities of RBD-specific mAbs to MERS-CoV EMC strain.

![](pone.0232757.t001){#pone.0232757.t001g}

  mAbs        Live MERS-CoV IC~50~ (μg/ml)   Pseudovirus IC~50~ (μg/ml)
  ----------- ------------------------------ ----------------------------
  KNIH77-A5   0.075                          0.1572 
  KNIH77-A6   0.030                          0.0089 
  KNIH90-E5   1.787                          0.9456 
  KNIH90-E6   N.D.                           N.D.
  KNIH90-F1   0.006                           0.0135
  KNIH90-F2   0.247                          0.2173 

The data are expressed as mean IC~50~ (n = 3). N.D.: Not Determined

Binding affinity of mAbs to S1 and the RBD {#sec019}
------------------------------------------

The binding affinity of the selected mAbs to immobilized RBD or S1 protein on a CM5 chip was assessed by SPR assay. The K~D~ (M) values for S1 ranged between 6.56 nM and \<0.0753 nM, whereas those for the RBD ranged between 5.85 nM and 0.016 nM. Because the K~d~ (1/s) values of KNIH77-A5 and KNIH77-B2 were above the device-detection limit (10^−5^ s^−1^), the results are presented using the inequality. KNIH77-A5 showed the highest affinity to both S1 and RBD proteins, whereas KNIH90-F1, which had the highest neutralizing ability, showed the next strongest affinity to RBD ([Table 2](#pone.0232757.t002){ref-type="table"}).

10.1371/journal.pone.0232757.t002

###### Binding affinity of mAbs with potent neutralizing activity to MERS-CoV spike.

![](pone.0232757.t002){#pone.0232757.t002g}

  mAbs        Binding kinetics for S1   Binding kinetics for RBD                                                                                         
  ----------- ------------------------- -------------------------- ------------------------------------------------------ -------------- --------------- ----------------
  KNIH77-A5   1.33 × 10^5^              ≤ 10^−5^                   ≤ 7.53× 10^−11^[\*](#t002fn001){ref-type="table-fn"}   1.29 × 10^5^   2.07 × 10^−5^   1.61 × 10^−11^
  KNIH77-A6   6.37 × 10^4^              4.42 × 10^−5^              6.94 × 10^−10^                                         4.67 × 10^4^   3.14 × 10^−5^   6.73 × 10^−10^
  KNIH90-B2   1.30 × 10^5^              ≤ 10^−5^                   ≤ 7.65× 10^−11^                                        \-             \-              \-
  KNIH90-B7   6.81 × 10^5^              1.04 × 10^−4^              1.52 × 10^−10^                                         \-             \-              \-
  KNIH90-F1   6.48 × 10^5^              9.88 × 10^−5^              1.52 × 10^−10^                                         3.76 × 10^5^   2.70 × 10^−5^   7.19 × 10^−11^
  KNIH90-F2   1.37 × 10^5^              8.81 × 10^−4^              6.59 × 10^−9^                                          2.38 × 10^5^   1.39 × 10^−3^   5.85 × 10^−9^

\* Values that exceeded T200 detection limit 10^-5^s^-1^

Computational structure modeling and the RBD and mAb interaction {#sec020}
----------------------------------------------------------------

The structures for the 240 amino acids of RBD and the variable region of KNIH90-F1 were predicted using I-TASSER and Antibody in the Rosetta online service. The RBD comprises seven α-helices (residues 385--9, 411--5, 430--5, 453--5, 463--8, 525--9, and 547--9) and 11 β-strands (residues 400--4, 407--9, 419--26, 438--47, 477--83, 497--507, 513--5, 538--44, 553--61, 568--76, and 583--6). The variable-region structure model of KNIH90-F1 was generated from residues 20 to 149 of the heavy chain and residues 20 to 129 of the light chain. A 14-amino acid peptide sequence of the complementarity determining region H3 loop for KNIH90-F1 was predicted at position 124SYGSGSYYTHYYAM137 of the heavy chain ([Fig 3A](#pone.0232757.g003){ref-type="fig"}). Modeled structures were used as the starting structures for docking simulation. According to the SnugDock protocol, these two structures were located very close to each other but did not superpose. Determination of the RBD interaction with KNIH90-F1 was performed by the SnugDock algorithm based on computational modeling of KNIH90-F1 and RBD protein sequences ([Fig 3B](#pone.0232757.g003){ref-type="fig"}). SnugDock alignment indicated that the RBD N-terminus couples to the KNIH90-F1 variable region through four RBD-interfacing peptide sequences: 528SI529, 538GDYYRKQ544, 544QLSPL548, and 551GGW553. Another three individual amino acid sites (S508, D510, and W553) of the MERS-RBD molecule also aligned closely with the KNIH90-F1 variable region ([Fig 3C](#pone.0232757.g003){ref-type="fig"}). The RBD residues (510D, 538GDY540, and 553W) attached to the KNIH90-F1 antibody are the same sites that interact with DPP4 \[[@pone.0232757.ref035]\]. The several residues (508S, 510D, 538G, 543KQLS546, 548L, 551GG552) of binding interface in KNIH90-F1 mAb were expected as novel binding resides in comparison with those of other MERS-CoV antibodies \[[@pone.0232757.ref010], [@pone.0232757.ref036], [@pone.0232757.ref037]\]. Five of the simulated binding-interface residues (510D, 539D, 540Y, 542R, and 553W) showed strong hindrance of RBD--hDPP4-receptor binding in the mAb m336 study \[[@pone.0232757.ref012]\]. These results indicated that KNIH90-F1 was capable of neutralizing MERS-CoV entry by preventing RBD attachment to DPP4.

![Proposed docked structure of the RBD and mAb.\
(A) A docked complex of the RBD and the KNIH90-F1 variable region. Green: RBD; cyan: heavy chain; magenta: light chain; red: interface residues of RBD with the heavy chain; pink: interface residues of the heavy chain; blue: interface residues of RBD with light chain (L); sky blue: interface residues of the light chain; yellow: overlapped interface residues in the heavy and light chains. (B) Interaction of the RBD and KNIH90-F1 complex. Interface residues of the RBD and heavy chain (left) and light chain (right). (C) Summarized putative interaction residues of the RBD, heavy chain, and light chain.](pone.0232757.g003){#pone.0232757.g003}

Efficacy of MERS-CoV mAbs in hDPP4 TG mice {#sec021}
------------------------------------------

The mAb KNIH90-F1 was selected for the animal study, because it exhibited the highest neutralizing potency *in vitro* assays. Human DPP4-expressing C57BL/6N TG mice were highly susceptible to MERS-CoV infection, demonstrating an analytical LD~50~ of wild-type MERS-CoV KNIH-002 of 1 × 10^3^ pfu ([S2 Fig](#pone.0232757.s002){ref-type="supplementary-material"}). To evaluate the therapeutic efficacy of KNIH90-F1, mice were challenged with a high dose (100 LD~50~) of the EMC strain. After 24 h, the mice were intraperitoneally administered KNIH90-F1 at different concentrations. Change in body weight and survival of mice were monitored for 14 days. All placebo (PBS)-treated mice died within 9-days post-infection ([Fig 4B](#pone.0232757.g004){ref-type="fig"}); however, groups treated with 50 μg (2 mg/kg) and 200 μg (8 mg/kg) of the mAb were completely protected from the lethal challenge and exhibited only a minimal body weight change ([Fig 4A](#pone.0232757.g004){ref-type="fig"}). The mice in group that received the lowest dose of the mAb (10 μg; 0.4 mg/kg) showed an 80% survival rate with significant weight loss and recovered after 8 days post-infection ([Fig 4B](#pone.0232757.g004){ref-type="fig"}).

![MERS-CoV RBD-specific mAb protects mice from lethal challenge.\
Five hDPP4 TG mice were intraperitoneally administered different doses of KNIH90-F1 24 h after intranasal inoculation with the MERS-CoV KNIH-002 strain (1 × 10^5^ pfu/30 μl). Body weight change (A) and survival (B) were monitored for 14 days.](pone.0232757.g004){#pone.0232757.g004}

To examine the viral loads of lung and brain tissues in both prophylactic and therapeutic settings, mice were sacrificed at 4-days post-infection. No infectious virus was detected in the brain for both the therapeutic and prophylactic administrations of the mAb. Similarly, infectious viruses were hardly detected in the lungs, with a \~5 log reduction as compared with the control group ([Fig 5A](#pone.0232757.g005){ref-type="fig"}). However, high numbers of copies of the viral genome were detected in the lungs, indicating that the residual viral genome or non-replicable viral particles persisted ([Fig 5B](#pone.0232757.g005){ref-type="fig"}). The previous report elucidated that the mice infected with MERS-CoV had shown the pathological changes, gross pathological changes, mononuclear cell infiltration and alveolar edema on day 4 and day 7 post-infection \[[@pone.0232757.ref013]\], we performed euthanasia on day 4 and 7 to analyze the therapeutic or prophylactic effect of mAbs. Histopathological changes, such as inflammatory cell infiltration, neurogenic necrosis, and perivascular inflammatory cell infiltration, were observed in lung and brain tissues of the untreated group, as described previously \[[@pone.0232757.ref013]\]. ([Fig 6](#pone.0232757.g006){ref-type="fig"}). Additionally, monocyte infiltration was observed in lung tissues of both KNIH90-F1-treated and PBS-treated groups at 4-days post-infection but not in brain tissues. Inflammatory monocyte infiltration was observed in the brains of PBS-treated mice 7-days post-infection, whereas mAb-treated mice showed no apparent brain lesions. These data suggest that MERS-CoV infection induced the influx of monocytes into the lungs and brains of infected mice in a time-dependent manner.

![MERS-CoV RBD-specific mAb inhibits viral replication in mouse tissues.\
Four mice were treated with the KNIH90-F1 mAb (8 mg/kg) 24 h after MERS-CoV KNIH-002 strain lethal challenge (1 × 10^5^ pfu/mouse) under therapeutic conditions. Moreover, four mice were infected with MERS-CoV 24 h after administration of the same amount of mAb under prophylactic conditions. At 4-days post-challenge, all mice were humanely sacrificed, and tissues (lung and brain) were collected for viral titer analysis by plaque assays (A) and real-time RT-PCR (B). Viral genome copies in tissues were determined by real-time RT-PCR targeting the *Orf1a* gene. Data represent the mean ± standard deviation. \**P* ≤ 0.05; \*\**P* ≤ 0.005; \*\*\**P* ≤ 0.0005.](pone.0232757.g005){#pone.0232757.g005}

![Histopathological changes of the lungs and brains in MERS-CoV-infected mice.\
Six mice were treated with the KNIH90-F1 mAb (8 mg/kg) 24 h after lethal challenge. At 4- and 7-days post-challenge, all mice were sacrificed, and lungs (A) and brains (B) were collected. Tissue sections were stained with H&E (magnification: 400×).](pone.0232757.g006){#pone.0232757.g006}

Discussion {#sec022}
==========

MERS-CoV cases have been reported continuously in the Middle East since the virus was first identified in April of 2012 \[[@pone.0232757.ref001]\]. The largest outbreak of MERS-CoV infections outside the Middle East occurred in Korea in 2015 and resulted in 186 laboratory confirmed cases with 38 deaths \[[@pone.0232757.ref003]\]. Since then, the importance of patient management, especially in hospitals, and preparedness against newly emerging infectious diseases has been emphasized from a public health perspective. Due to the absence of approved vaccines and virus-specific antiviral agents, an alternative antiviral-treatment guideline for MERS-CoV patients involving the triple administration of type I interferon, ribavirin, and lopinavir/ritonavir for 10 to 14 days was recommended in South Korea \[[@pone.0232757.ref038]\]. However, side effects of this triple administration and significantly low therapeutic efficacy of ribavirin and interferon for severe MERS cases have been reported \[[@pone.0232757.ref039]--[@pone.0232757.ref042]\]. Therefore, a virus-specific neutralizing antibody regimen could be proposed as an alternative treatment.

In this study, single B cells were directly isolated from the PBMCs of convalescent MERS-CoV-infected Korean patients using flow cytometry cell sorter with a prefusion MERS-CoV S-2P probe and/or S1, and the IgG genes were promptly cloned for expression in mammalian cells. Previous reports, including MERS-CoV, SARS-CoV, HIV and RSV, showed that structure-designed stabilization of the viral surface protein by mutations or multivalent display induced greater neutralizing mAbs than postfusion proteins \[[@pone.0232757.ref020]--[@pone.0232757.ref023]\]. Accordingly, we reasoned that the prefusion S-2P probe could bind greater neutralizing antibodies on the surface of single B cells than wild S protein. Considering the duration from the isolation of single B cells to the purification of IgGs, we obtained total 11 mAbs rapidly within one month by using this antibody technology. All these mAbs had high specificity, bound to only the cells infected with MERS-CoV, not other coronaviruses in the IFA experiment.

Among the six RBD-specific mAbs obtained, the most potent neutralizing antibody was KNIH90-F1, which showed exceptional therapeutic efficacy in the mouse model. In line with other studies, the RBD-specific antibodies showed high neutralizing activity, whereas the IC~50~ values from the live-virus-based assay varied widely \[[@pone.0232757.ref006]--[@pone.0232757.ref010], [@pone.0232757.ref012], [@pone.0232757.ref043]\]. It is speculated that RBD-specific mAbs, such as LCA60 (IC~50~ = 0.110--0.279 μg/ml), MERS-GD27 (IC~50~ = 0.001 μg/ml) and KNIH90-F1 (IC~50~ = 0.006 μg/ml), generated directly from patient B cells repertoires are more potent and are thus more likely to neutralize wild-type viruses. However, among the S1 (non-RBD) mAbs, only KNIH90-B2 and KNIH90-B7 showed mild neutralizing ability against the live virus (failed to reach the IC~50~ value). The N-terminal domain (NTD) of S1 binds sialic acid of host cellular receptors \[[@pone.0232757.ref044]\], and non-RBD mAbs targeting the NTD of S1 also show neutralizing activity \[[@pone.0232757.ref005]\]. We assumed that KNIH90-B2 and KNIH90-B7 could bind to NTD of S1, resulting the mild neutralization via preventing the viral attachment to the sialic acid of cellular receptors. However, no S2-specific antibody was isolated from patient PBMCs in the present study. This might be attributed to the lower immunogenicity of the S2 than the S1 domain, as is the case for the influenza virus HA2 stalk domain \[[@pone.0232757.ref045]\]. The practical use of antibody cocktails has been used for Ebola virus \[[@pone.0232757.ref046], [@pone.0232757.ref047]\], hepatitis C virus \[[@pone.0232757.ref048]\], and MERS-CoV \[[@pone.0232757.ref017]\] to prevent the emergence of escape mutants as well as enhance the neutralization breadth. We suggest that combining RBD mAbs and non-RBD mAbs, targeting multiple antigenic sites on MERS-CoV spike, need to be implemented for treating future MERS-CoV infection.

As MERS-CoV does not naturally infect mice, we employed TG mice that systemically expressed the human receptor hDPP4 for the challenge experiment. All KNIH90-F1-treated mice survived after challenge with an extremely high dose (100 LD~50~; 1 × 10^5^ pfu/mouse) of the virus, including those that received the low dose (2 mg/kg) of mAbs, reflecting the potent therapeutic efficacy of this mAb. Additionally, the residual live-virus particles were not detected in the lungs by 4-days post-infection in both the therapeutic and prophylactic administration groups. Even with a significant amount of viral genome in the lungs, MERS-CoV infection rarely occurred through plaque assays. It was estimated that the KNIH90-F1 mAb administered to the animal model remained in the tissues or attached to the virus and neutralized its infectivity. Although there is substantial heterogeneity in drug disposition and pharmacokinetics of mAbs, the half-life of mAbs is generally 14 days (7--21 days) \[[@pone.0232757.ref049]\]. We sacrificed the mice administered with KNIH90-F1 mAb on the post-infection four days. Therefore, we assumed that a sufficient amount of mAb in the lungs could block the remained MERS-CoV infection in plaque assays.

Despite the promise of our developed mAbs, there are several limitations of this study that should be addressed in the future. First, escape mutants are more likely to occur when cultured viruses are continuously exposed to RBD-specific antibodies \[[@pone.0232757.ref010], [@pone.0232757.ref015]\]. Because KNIH90-F1 recognizes similar RBD domains, the efficacy of combined therapy with non-RBD S1 antibodies or RBD antibodies targeting different epitopes on the RBD should be evaluated to reduce the potential for escape mutations. In addition to direct receptor inhibition, indirect Fc-receptor-mediated immune responses, such as antibody dependent cellular cytotoxicity and complement-dependent cytotoxicity, should also be investigated. Second, due to the limited availability of TG mice, survival analysis following prophylactic administration was not completed. Only a pathogenic study that included measurements of viral titers in lung and brain tissues and histopathology were conducted. Therefore, additional animal experiments should be performed to assess complete prophylactic efficacy. Third, computer-assisted structural docking modeling suggested that the putative interacting residues on RBD are similar to those published previously \[[@pone.0232757.ref005], [@pone.0232757.ref008], [@pone.0232757.ref012]\]; however, more precise epitope mapping, such as that utilizing X-ray crystallography or RBD point-mutation analysis, is needed to resolve the exact epitope structure.

In conclusion, we generated a highly potent human neutralizing mAb (KNIH90-F1) against MERS-CoV infection by using a prefusion-stabilized S-2P probe, and a direct IgG cloning platform from isolated B cells. This approach could be promptly applied for newly emerging viruses potentially threatening public health in the future. The KNIH90-F1 mAb could represent a potential candidate for development of a novel MERS therapeutic agent, as well as a prophylactic treatment. Moreover, it could be used in combination with other mAbs targeting different RBD epitopes or non-RBD mAbs for practical MERS immunotherapy.

Supporting information {#sec023}
======================

###### Neutralizing activity of KNIH90-F1.

Neutralization potency of the RBD-specific mAb KNIH90-F1 was evaluated by a PRNT assay using low mAb concentrations (0.00025--0.25 μg/ml). Percent inhibition by the mAb was determined by comparison with untreated cells (A). The IC~50~ value was determined by nonlinear regression curve fitting (B). Each experiment was performed in triplicate, and data represent the mean of each experiment with standard errors.

(TIF)

###### 

Click here for additional data file.

###### Determination of 50% mouse lethal dose (LD~50~).

\(A\) Body weight loss curve of 10-week-old male C57BL/6N-hDPP4 mice (n = 5 per group) infected with different doses of MERS-CoV KNIH-002. The error bar indicate the standard error of the mean. The weight loss and survival were monitored for 14 days.

(TIF)

###### 

Click here for additional data file.

###### Specificity of human monoclonal antibodies for MERS-CoV.

IFA was performed as described previously \[[@pone.0232757.ref027]\]. Briefly, Vero cells were infected with MERS-CoV Erasmus (EMC) strain and SARS-CoV-2 isolated from a Korean patient \[[@pone.0232757.ref050]\]. MRC5 cells were infected with human coronaviruses (hCoV) OC-43 strain (ATCC, Manassas, VA, USA) and 229E strain (ATCC). LLC-MK2 cells were infected with hCoV NL63 strain (CN061/14). After the cytopathogenic effect appeared in the infected cells, the cells were fixed with 70% methanol in PBS. Then, human anti-MERS-CoV antibodies were incubated with the Vero cells infected with MERS-CoV. As positive controls, a rabbit polyclonal anti-MERS-CoV spike protein antibody (Sino biological Inc., Beijing, China) for MERS-CoV, a mouse anti-229E coronavirus nucleoprotein OC-43 antibody (MERCK, Darmstadt, Germany) for HCoV-229E, a mouse anti-coronavirus antibody, hCoV OC-43 (LifeSpan BioScience, Seattle, WA, USA) for HCoV-OC43, a rabbit polyclonal anti-hCoV-HKU1 spike protein antibody (Sino Biological Inc., Beijing, China) for hCoV-NL63, a human serum of a Korean SARS-CoV-2 convalescent person were also incubated. The IFA performed without the positive primary antibodies (described above) were used as negative controls. The secondary antibodies, Fluorescein isothiocyanate (FITC) -conjugated goat anti-human-IgG (Abcam, Cambridge, U.K.), FITC-conjugated goat anti-rabbit-IgG (Abcam, Cambridge, U.K.), and FITC-conjugated goat anti-mouse-IgG (Jackson Immunoresearch, West Grove, PA, USA) were added to the cells and incubated. The cells were observed, and images were obtained using a fluorescence microscope.

(TIF)

###### 

Click here for additional data file.
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2\. Has the statistical analysis been performed appropriately and rigorously?
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3\. Have the authors made all data underlying the findings in their manuscript fully available?
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Reviewer \#3: Yes
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4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes
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5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: This study describes the isolation and recombinant production of a set of MERS CoV-specific IgG, in vitro functional testing of specific clones and subsequent testing of a single clone for its therapeutic potential in an experimental infection mouse model. The manuscript is well written although type-editing is required to improve readability. The data supports the overall conclusion that the tested clone is a potential candidate as a prophylactic or therapeutic antiviral but more detailed and larger studies are warranted to substantiate this claim. Several points need to be addressed to corroborate and clarify their findings as listed below.

General comments:

The rationale for choosing S-2P as a bait for isolation of B cells is not explained clearly or emphasized enough.

Only a single clone is tested for its therapeutic potential in vivo, despite the functional differences observed in vitro. Therefore, the impact of in vitro differences is not assessed. Other monoclonal antibodies with therapeutic potential from this study or another publication for a complete evaluation of KNIH90-F1 potential would be of added value.

These data should be confirmed by mutations in recombinant protein and assessment of binding, or generation of neutralization escape mutants.

The statistics main section, as well as its description at the figure legends, is too simplified and should be more accurately described (correctly referencing replicates per experiment and the test that was performed).

Specific comments:

• Line 49: please update since this reference is almost 1 year old.

• Line 57: neutralizing antibodies do not bind the host receptor, but instead bind the viral RBD to prevent its binding to the receptor.

• Line 63, please remove "Chinese"and "Korean" from the main text, as this detail is already in the reference.

• Line 71: you only reference results from 1 clinical trial, what about the humanized mAbs (REGN)?

• Line 106: specify the gravitational force at 1500 rpm

• Line 110: the authors need to provide more information about the gating strategy and sorting of S-2P and S1 specific B cells. An explanation for choosing the specific mix of antibodies is missing.

• Line 113: the usage of S1 in combination with fluorescently labeled S-2P for B cell sorting is not explained.

• Line 119: heading needs to be more specific

• Line 141: a more detailed explanation of the evaluation of the antibody sequences using IMGT-QUEST tool is missing.

• Line 152: the reason why S2 fused with murine Fc is used for ELISA is not specified.

• Line 201: please replace "C196ages" with Cages.

• Line 216, 224, 229: day 4 and day 7 post-infection euthanasia is not argued.

• Line 217: it is not specified why only brain and lung tissues were selected for pathology studies. The authors do not specify the weight of tissue that was analyzed in each case, which is necessary for comparison of titers as titers are represented as pfu/g.

• Line 218. Please provide details on how the plaque assay was performed.

• Line 226: First line should be moved to previous section.

• Line 233: Please specify how the number of genome copies is determined.

• Line 248: PBMCs of five different convalescent MERS patients were isolated, but only three were used. Nothing is mentioned about the other two patients or why these 3 were selected.

• Line 252: it is not specified how these 90 B cells were selected for sorting, and which patients' they were isolated from. Furthermore, sequences of variable heavy chain and kappa or lambda light chain regions should be submitted to an online database, such as GenBank, for future reference.

• Line 259: the meaning of this sentence is unclear. An S2 antibody was not identified although this domain is relatively conserved as compared to S1?

• Line 285: Compared to what strain, EMC?

• Line 291, Table 1: the number of replicates performed on this experiment is not specified.

• Line 334: These data should be confirmed by mutations in recombinant protein and assessment of binding, or generation of neutralization escape mutants.

• Line 365: What is the rational for selectively examining lung and brain tissues? Longitudinal analysis of swabs and peripheral blood would be of added value.

• Line 366: what is the rationale for selecting day 4?

• Line 369: or more likely, as indicated in the discussion, the presence of neutralizing antibody will neutralize any infectious virus when titrating.

• Line 374: on what data do the authors base the "time-dependent manner"?

• Line 374: infiltration of monocytes should be quantified in order to determine differences.

• Line 414: the term "wild S-probe" is incorrect.

• Line 422: the meaning of this sentence is not clear. No data is available that allows speculation on how "intact" the repertoire of B-cells using different methods to isolate specific clones. What is meant by "intact"? does this refer to how representative the B-cell repertoire is?

• Line 441: "superior therapeutic efficacy" can only be claimed when testing the antibodies side-by-side in the same model.

• Line 448: the explanation on the choice of post-infection day for euthanasia could be more detailed (and maybe placed in a different section).

• Line 453: evaluation of neutralization activity of KNIH90-F1 should be already evaluated on escape mutants.

Figure 1: Technical or experimental replicates are not specified.

Figure 2A: Lack of error bars suggests a single measurement is performed, yet legend suggests triplicates. Please clarify. Title on right graph has a type error.

Figure 3B: It is not clear on what protein each aa is located in this graphical representation. The use of for instance colored fonts may help to clarify.

Reviewer \#2: Currently there are no approved therapies for MERS. Many groups have focused on the identification and characterization of antibodies against MERS-CoV. Now Choi et al., analysed a human monoclonal antibody generated from a B cell specific for a prefusion-stabilized spike protein of Middle East respiratory syndrome coronavirus. Overall, the methods used are sound and the manuscript is well written. However, I have one major issue with this manuscript. The authors use the prefusion-stabilized spike protein and claim that the antibodies are specific for the prefusion form. This is not the case. In fact this has not been demonstrated in the study, there is no specific interaction with this prefusion form, the antibodies recognize also the S1 protein they use\...

The confusion to me starts in the methods section where they indicate that B cells are sorted that are positive for the spike prefusion protein AND S1. So the authors should comment on that in detail because there is no specific selection of prefusion antibodies. If this indeed is the case the manuscript should be rewritten to take out this claim.

Furthermore, antibodies to S1 that do not recognize RBD are not well characterized. The suggest these recognize the A domain, but this has not been analyse. Studies to show the antigen specificity need to be provided.

Reviewer \#3: Re: PONE-D-19-34811

The manuscript, entitled "Characterization of a human monoclonal antibody generated from a B cell specific for a prefusion-stabilized spike protein of Middle East respiratory syndrome coronavirus" by Jang-Hoon Choi, et al, describes novel human monoclonal antibodies specific to MERS-coronavirus spike protein developed by cell-sorting of B cells obtained from MERS-recovered patients. The RBD-recognizing antibodies exhibit a high neutralization potency against MERS-CoV in vitro. Among them, one MAb (KNIH90-F1) is effective for prophylaxis or treatment of MERS-CoV infection in mice model. Overall the presented data are convincing. Although the development of therapeutic candidates of anti-MERS-CoV MAb is very important, a major concern is the lack of novel contribution to research on anti-MERS-CoV MAb except for B-cell sorting methodology. As authors have already mentioned, there are already several reports describing MAbs with therapeutic and prophylactic potential against MERS-CoV infection.

Several points that need to be described in the text.

1\. It is not clear what is concluded from the data showing MAb binding affinity (Table 2) and 3D structure modeling (Fig.3). Most of the data can be omitted.

2\. Line 80 or 469, how can you say "fastest" or "rapidly and conveniently"?

3\. Line 143, an information of expression vector (plasmid name, company, etc) is missing.

4\. Line 165, please indicate the details of the pseudovirus. Is this express luciferase, GFP, or others? Also, this information should be included in figure 2.

5\. Line 261, "as this domain is relatively conserved..." seems to be incorrect. S1 positive clones were selected in the B cell sorting as described in materials and methods (line 113). The same thing seems to be applied to line 429 "no S2-specific antibody was isolated...".

6\. Line 283, table 1 does not indicate the data of "no difference between IC50 values of MERS-CoV EMC and KNIH-002..".

7\. Line 285, "change" should be "differences".

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).
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Reviewer \#1: This study describes the isolation and recombinant production of a set of MERS CoV-specific IgG, in vitro functional testing of specific clones and subsequent testing of a single clone for its therapeutic potential in an experimental infection mouse model. The manuscript is well written although type-editing is required to improve readability. The data supports the overall conclusion that the tested clone is a potential candidate as a prophylactic or therapeutic antiviral but more detailed and larger studies are warranted to substantiate this claim. Several points need to be addressed to corroborate and clarify their findings as listed below.

General comments:

The rationale for choosing S-2P as a bait for isolation of B cells is not explained clearly or emphasized enough.

☞ We added the explanation of reference 20 in Introduction to explain why we chose S-2P as a bait. At first, S-2P was expressed by 20-fold dramatically as well as it induced more neutralizing antibodies in mice, compared to wild S, as described previously such as SARS-CoV, HIV, and RSV (reference 20, 21, 22, and 23) in line 84-86. Thus, we hypothesized that structure-designed stabilized viral surface proteins could bind the neutralizing antibodies of convalescent patients' B cells more efficiently than wild-type protein.

Only a single clone is tested for its therapeutic potential in vivo, despite the functional differences observed in vitro. Therefore, the impact of in vitro differences is not assessed. Other monoclonal antibodies with therapeutic potential from this study or another publication for a complete evaluation of KNIH90-F1 potential would be of added value.

☞ We agreed with your opinion. At first, we have been testing the synergic effect of antibody cocktails in vitro assays. Then, we will try the combination test for the therapeutic efficacy in animal model. However, it requires lots of time, labors, and transgenic mice. The minimum two months are needed to produce the amount of hDPP4 transgenic mice sufficient for the animal tests. We will show the further result later.

These data should be confirmed by mutations in recombinant protein and assessment of binding, or generation of neutralization escape mutants.

☞ We agreed with your opinion. We have processed several immune escape mutants in the case of KNIH90-F1. We are also going to test pseudoviruses having Spike protein mutants to confirm whether the mutation site may be critical to the neutralizing antibodies. We will prepare this result for another publication.

The main statistics section, as well as its description at the figure legends, is too simplified and should be more accurately described (correctly referencing replicates per experiment and the test that was performed).

☞ According to your advice, we added more explanation to the statistics at the figure legends.

Specific comments:

? Line 49: please update since this reference is almost 1 year old.

☞ We update the reference, 2,519 laboratory-confirmed patients and 866 deaths (34.3 % mortality) have been reported as of January 2020 in line 49-50.

? Line 57: neutralizing antibodies do not bind the host receptor, but instead bind the viral RBD to prevent its binding to the receptor.

☞ We correct the sentence, "Several laboratory studies proposed vaccine candidates based on the receptor-binding domain (RBD) of spike (S) antigen, which induce neutralizing antibodies that inhibit RBD from binding the host receptor dipeptidyl peptidase 4 (hDPP4; also known as CD26) \[4\]" in line 56-69.

? Line 63, please remove "Chinese"and "Korean" from the main text, as this detail is already in the reference

☞ We removed the words "Chinese" and "Korean" in line 64-65.

? Line 71: you only reference results from 1 clinical trial, what about the humanized mAbs (REGN)?

☞ We try to update the result of the clinical trial for humanized mAbs (REGN3048 and REGN3051); however, we could not get any result from ClinicalTrials.gov, pubmed, Google and the website of Regeneron, except the result of marmosets (Antiviral Res. 2018 Aug;156:64-71.)

? Line 106: specify the gravitational force at 1500 rpm

☞ We corrected 1,500 rpm to 200 g force in line 110.

? Line 110: the authors need to provide more information about the gating strategy and sorting of S-2P and S1 specific B cells. An explanation for choosing the specific mix of antibodies is missing.

☞ As we mentioned before, we added the explanation of reference 20 (Pallesen J, Wang N, Corbett KS, Wrapp D, Kirchdoerfer RN, Turner HL, et al. Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen. Proc Natl Acad Sci U S A. 2017;114(35):E7348-e57.) in Introduction to explain why we chose S-2P as a bait. At first, S-2P was expressed by 20-fold dramatically as well as it induced more neutralizing antibodies in mice, compared to wild S, as described previously such as SARS-CoV, HIV, and RSV (reference 20, 21, 22, and 23). We hypothesized that structure-designed stabilized viral surface proteins could bind the neutralizing antibodies of convalescent patients' B cells more efficiently than wild-type proteins.

? Line 113: the usage of S1 in combination with fluorescently labeled S-2P for B cell sorting is not explained.

☞ We described two probes usage in the line 118.

? Line 119: heading needs to be more specific

☞ We corrected the heading in line 125.

? Line 141: a more detailed explanation of the evaluation of the antibody sequences using IMGT-QUEST tool is missing.

☞ We added more explanation in the sentence in line 146-148.

? Line 152: the reason why S2 fused with murine Fc is used for ELISA is not specified.

☞ We added more explanation in the sentence since murine Fc was tagged to S2 to improve in vitro solubility and stability when expressed in the cells in line 160-161.

? Line 201: please replace "C196ages" with Cages.

☞ We corrected it in line 209.

? Line 216, 224, 229: day 4 and day 7 post-infection euthanasia is not argued.

☞ According to the reference 13 (Stalin Raj V, Okba NMA, Gutierrez-Alvarez J, Drabek D, van Dieren B, Widagdo W, et al. Chimeric camel/human heavy-chain antibodies protect against MERS-CoV infection. Sci Adv. 2018;4(8):eaas9667.), the mice infected with MERS-CoV showed the pathological changes, gross pathological changes, mononuclear cell infiltration and alveolar edema on day 4 and day 7 post-infection, we performed euthanasia on both time to analyze the therapeutic effect of mAbs. We added the explanation in the result text.

? Line 217: it is not specified why only brain and lung tissues were selected for pathology studies. The authors do not specify the weight of tissue that was analyzed in each case, which is necessary for comparison of titers as titers are represented as pfu/g.

☞ According to the reference 31 (Agrawal AS, Garron T, Tao X, Peng BH, Wakamiya M, Chan TS, et al. Generation of a transgenic mouse model of Middle East respiratory syndrome coronavirus infection and disease. Journal of virology. 2015;89(7):3659-70.), high infectious virus titers were detected from the lungs and brains of mice on day 4 post-infection, whereas viral RNAs were also detected in the heart, spleen, and intestine, indicating a disseminating viral infection.

Moreover, infected transgenic mice were able to activate genes encoding for many antiviral and inflammatory mediators within the lungs and brains, coinciding with the high levels of viral replication. Therefore, we determined to measure viral titers in the lungs and brains. We also measured the brain and lung tissue weights after we harvested the tissues. We added the phrase "After brain and lung tissue weights were measured" (line 227-228).

? Line 218. Please provide details on how the plaque assay was performed.

☞ We added the protocol in Methods of "Assessment of therapeutic and prophylactic effects of mAb in mice."

To measure the virus titration, tissues were homogenized in DMEM using a manual homogenizer and centrifuged for 10 min. Viral RNAs were extracted from the supernatant by Maxwell RSC Viral TNA kit (Promega). They were assayed by using PowerChekTM MERS (upE & ORF1a) Real-time RT-PCR kit (Kogene biotech) according to the manufacturer\'s instructions. Vero cell monolayers were inoculated with serial 10-fold dilutions of the supernatant, which was adsorbed for 1 hr. The cells were covered with 1 ml or 1.5% CMC solution. After 3 days, the cells were washed with PBS and fixed with 4% formaldehyde and stained with crystal violet.

? Line 226: First line should be moved to previous section.

☞ We found that the same experiment was described in the "Assessment of therapeutic and prophylactic effects of mAb in mice" and "Histology". Thus, we corrected the first line to "Six mice in each group were performed according to the same experiment design for the therapeutic efficacy in the previous section" to avoid the sentence duplication according to your advice (line 258-259).

? Line 233: Please specify how the number of genome copies is determined.

☞ We added the method "Assessment of therapeutic and prophylactic effects of mAb in mice" to specify how to construct standard RNAs and to calculate the number of genome copies. Briefly, upE of MERS-CoV RT-PCR was performed with SuperScript III reverse transcriptase (Invitrogen, Carlsbad, CA, USA) using MERS-CoV EMC as an RNA template. For PCR, 5 μl of the RT reaction was added to 20 μl of PCR amplification master mix containing Ex-Taq™ polymerase (Takara, Shuzo, Japan). After PCR purification with a PCR purification kit (Qiagen), 1 μl of pCR®2.1-TOPO® vector (Invitrogen) was added to the purified PCR products, and the mixture was transformed into One Shot® Top10 competent cells (Invitrogen). The standard RNAs were synthesized massively using a MEGAscript® T7 kit (Applied Biosystems) and the template plasmids pCR2.1-upE. The RNAs were purified by MEGAclear™ kit (Applied Biosystems). RNA copy numbers were calculated based on RNA concentration and size. The upE RNA fragment was diluted serially with a 0.5 log-dilution to yield 1 to 105 copies per reaction, and these dilutions were then used as templates for rRT-PCR. We calculated the Ct values of tissues and copy numbers.

? Line 248: PBMCs of five different convalescent MERS patients were isolated, but only three were used. Nothing is mentioned about the other two patients or why these 3 were selected.

☞ Initially we prepared PBMCs from 5 patients but used those from only 3 patients therefore we corrected it (line 279).

? Line 252: it is not specified how these 90 B cells were selected for sorting, and which patients' they were isolated from. Furthermore, sequences of variable heavy chain and kappa or lambda light chain regions should be submitted to an online database, such as GenBank, for future reference.

☞ We added more explanation in the sentence to describe how to sort B cells. The amino acid sequences were reported by the patent ("MONOCLONAL ANTIBODY FOR SPIKE PROTEIN OF MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS, AND USE THEREOF" and No. 10-1895229 (Korean patent) (PCT application No. PCT KR2018009754)). Also, the gene sequences will be submitted to GenBank.

? Line 259: the meaning of this sentence is unclear. An S2 antibody was not identified although this domain is relatively conserved as compared to S1?

☞ We agreed with you, we corrected the sentence not to make confusion. S2 domain is more conserved than S1 but we did not get any S2 specific antibody. Therefore, it seems to be less immunogenicity (line 290-292).

? Line 285: Compared to what strain, EMC?

☞ You're right, we added "compared to EMC stain."

? Line 291, Table 1: the number of replicates performed on this experiment is not specified.

☞ We agreed with you, so we added the table description more, " The data are expressed as mean IC50 (n=3)." Additionally, we corrected sentence materials and methods (line 180).

? Line 334: These data should be confirmed by mutations in recombinant protein and assessment of binding, or generation of neutralization escape mutants.

☞ We agreed with your opinion, we also have thought that further studies were needed. We have found that several escape mutants of MERS-CoV from KNIH90-F1, KNIH90-B2, and KNIH90-F2. We are also analyzing X-ray crystallography of KNIH90-F1 and RBD. To gather all the data will require some time. We are going to show this result for another publication.

? Line 365: What is the rational for selectively examining lung and brain tissues? Longitudinal analysis of swabs and peripheral blood would be of added value.

☞ According to reference 13 and 31, high infectious virus titers and histopathology were detected in the lungs and brains of mice, thus we determined to examine lung and brain tissues for the therapeutic efficacy in vivo. However, we are also trying to analyze the tissue distribution of MERS-CoV, including swabs and peripheral blood, in our transgenic mice. This result will be published in detailed.

? Line 366: what is the rationale for selecting day 4?

☞ As we mentioned previously, according to reference 13 and 31, high infectious virus titers were detected from the lungs and brains of mice on day 4 post-infection, thus we sacrificed the mice on 4 days post-infection.

? Line 369: or more likely, as indicated in the discussion, the presence of neutralizing antibody will neutralize any infectious virus when titrating.

☞ We are the same as your comments. The presence of KNIH90-F1 in the blood will neutralize the MERS-CoV when titrating.

? Line 374: on what data do the authors base the "time-dependent manner"?

? Line 374: The infiltration of monocytes should be quantified in order to determine differences.

☞ The sentence has been rearranged to clarify (line 416-417). Unfortunately, we did not quantify infiltration of monocytes. However, pathologic analysis was performed by an authorized histopathological laboratory (ChemOn Inc., Suwon, South Korea). To help understand the histopathological information, we attached the pathological score table of the lungs and brains from ChemOn Inc. They scored pathology in tissue slides according to Pristima Glossary and INHAND of the book "Standardized System for Nomenclature and Diagnostic Criteria ? Guides for Toxicologic Pathology (Xybion)". (Score: from minimal (+1) to massive pathology (+5), Number examined of each group=3)

According their report, the pathological change and infiltration of mononuclear cells in lungs and brains after MERS-CoV infection had been processed more severely on 7 days post-infection than 4 days post-infection. Therefore, we thought the pathological change, such as the influx of monocyte into the lungs and brains, become more serious in a time-dependent manner.

(You can see the table in the word file)

? Line 414: the term "wild S-probe" is incorrect.

☞ We corrected it to "wild S protein" (line 454).

? Line 422: the meaning of this sentence is not clear. No data is available that allows speculation on how "intact" the repertoire of B-cells using different methods to isolate specific clones. What is meant by "intact"? does this refer to how representative the B-cell repertoire is?

☞ We agree with your comment and corrected the sentence line 464.

? Line 441: "superior therapeutic efficacy" can only be claimed when testing the antibodies side-by-side in the same model.

☞ According to your comments, we deleted the previous reports and then, we correct "superior" to "potent" and deleted the comparison (line 481-482).

? Line 448: the explanation on the choice of post-infection day for euthanasia could be more detailed (and maybe placed in a different section).

☞ As we mentioned previously, we chose post-infection 4 days and 7 days according to reference 13 and 31.

? Line 453: evaluation of the neutralization activity of KNIH90-F1 should be already evaluated on escape mutants.

☞ As we mentioned previously, we have processed several immune escape mutants for the evaluation of the neutralization of KNIH90-F1.

? Figure 1: Technical or experimental replicates are not specified.

☞ We added the sentence, "Data points represent the mean of three technical replicates with standard errors" in figure 1 legend.

? Figure 2A: Lack of error bars suggests a single measurement is performed, yet legend suggests triplicates. Please clarify. Title on right graph has a type error.

☞ We added the error bars on figure 2.

Figure 3B: It is not clear on what protein each aa is located in this graphical representation. The use of for instance colored fonts may help to clarify.

☞ We change the colors of amino acids to clarify Figure 3B.

Reviewer \#2: Currently there are no approved therapies for MERS. Many groups have focused on the identification and characterization of antibodies against MERS-CoV. Now Choi et al., analysed a human monoclonal antibody generated from a B cell specific for a prefusion-stabilized spike protein of Middle East respiratory syndrome coronavirus. Overall, the methods used are sound and the manuscript is well written. However, I have one major issue with this manuscript. The authors use the prefusion-stabilized spike protein and claim that the antibodies are specific for the prefusion form. This is not the case. In fact this has not been demonstrated in the study, there is no specific interaction with this prefusion form, the antibodies recognize also the S1 protein they use\...

The confusion to me starts in the methods section where they indicate that B cells are sorted that are positive for the spike prefusion protein AND S1. So the authors should comment on that in detail because there is no specific selection of prefusion antibodies. If this indeed is the case the manuscript should be rewritten to take out this claim.

☞ In this study, we used prefusion S trimer and S1 for B cell selection. We collected all prefusion S trimer and/or S1 positive B cells and tested antibodies specificity by ELISA with S trimer, S1, RBD, S2 protein. Although these also bind to S1 and RBD, there is no direct evidence for the prefusion trimer specific antibody. Only KNIH90-C4 bound to prefusion S trimer more strongly than S1 protein in ELISA (Figure 1B) in line 292. Therefore we revised the sentence in line 509 and changed methods section (line 118).

Furthermore, antibodies to S1 that do not recognize RBD are not well characterized. The suggest these recognize the A domain, but this has not been analyse. Studies to show the antigen specificity need to be provided.

☞ We agree with your comment. We only tested S1 (non-RBD) antibodies with ELISA so we can't describe specificity of those antibodies. That is the one of this study limitation and will be resolved by epitope mapping. Therefore, we just assumed possibility of those antibody specificity in line 482-483.

Reviewer \#3: Re: PONE-D-19-34811

The manuscript, entitled "Characterization of a human monoclonal antibody generated from a B cell specific for a prefusion-stabilized spike protein of Middle East respiratory syndrome coronavirus" by Jang-Hoon Choi, et al, describes novel human monoclonal antibodies specific to MERS-coronavirus spike protein developed by cell-sorting of B cells obtained from MERS-recovered patients. The RBD-recognizing antibodies exhibit a high neutralization potency against MERS-CoV in vitro. Among them, one MAb (KNIH90-F1) is effective for prophylaxis or treatment of MERS-CoV infection in mice model. Overall the presented data are convincing. Although the development of therapeutic candidates of anti-MERS-CoV MAb is very important, a major concern is the lack of novel contribution to research on anti-MERS-CoV MAb except for B-cell sorting methodology. As authors have already mentioned, there are already several reports describing MAbs with therapeutic and prophylactic potential against MERS-CoV infection.

Several points that need to be described in the text.

1\. It is not clear what is concluded from the data showing MAb binding affinity (Table 2) and 3D structure modeling (Fig.3). Most of the data can be omitted.

☞ Structural analysis of antigen-antibody binding in computational methods can provide a breakthrough in the development of new antibodies. In this paper, we predicted the binding structure of antigen-antibody and predicted the regions and sites involved in these binding. Correlation between antigen-antibody binding capacity and predicted binding structure could not be obtained. We are going to analyze the X-ray crystallography between KNIH90-F1 and RBD in further study.

2\. Line 80 or 469, how can you say "fastest" or "rapidly and conveniently"?

☞ We removed those phrases.

3\. Line 143, an information of expression vector (plasmid name, company, etc) is missing.

☞ We added vectors\' name.

4\. Line 165, please indicate the details of the pseudovirus. Is this express luciferase, GFP, or others? Also, this information should be included in figure 2.

☞ We used luciferase based pseudovirus assay. We corrected the sentence to describe in detail, "Pseudovirus-neutralization assay (for EMC) with luciferase activity \[15\] and PRNT assay (for EMC and MERS-CoV/KOR/KNIH/002_05_2015 (KNIH-002) strains) were performed as described previously \[26\]"

5\. Line 261, "as this domain is relatively conserved..." seems to be incorrect. S1 positive clones were selected in the B cell sorting as described in materials and methods (line 113). The same thing seems to be applied to line 429 "no S2-specific antibody was isolated...".

☞ We agreed with you, we corrected the sentence not to make confusion. S2 domain is more conserved than S1 but we did not get any S2 specific antibody. Therefore, it seems to be less immunogenicity.

6\. Line 283, table 1 does not indicate the data of "no difference between IC50 values of MERS-CoV EMC and KNIH-002."

☞ We removed that sentence.

7\. Line 285, "change" should be "differences".

☞ We corrected it.

10.1371/journal.pone.0232757.r003
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Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <https://www.editorialmanager.com/pone/>, click the \"Update My Information\" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

With kind regards,

Stefan Pöhlmann, Ph.D.

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: All comments have been addressed

Reviewer \#2: All comments have been addressed

Reviewer \#3: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: (No Response)

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: (No Response)

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: (No Response)

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: No

Reviewer \#2: (No Response)

Reviewer \#3: Yes
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The concerns in the first manuscripts were well addressed by the revision.

Minor points:

1\) line 229-241, methodology to generate standard RNA should be moved to the section "Real-time RT-PCR for virus detection".

2\) line 413, the data is not "time-dependent manner", since monocyte infiltration was observed in lung at 4dpi. Also, the word "time-dependent manner" is usually used for quantitative data in the time-course experiments. The sentence can be omitted.

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

Reviewer \#3: No
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